LT4052B - Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof - Google Patents

Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof Download PDF

Info

Publication number
LT4052B
LT4052B LT96-028A LT96028A LT4052B LT 4052 B LT4052 B LT 4052B LT 96028 A LT96028 A LT 96028A LT 4052 B LT4052 B LT 4052B
Authority
LT
Lithuania
Prior art keywords
compound
crystalline anhydrous
temperature
composition
salt
Prior art date
Application number
LT96-028A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT96028A (en
Inventor
Roger Cherng Fu
De-Mei Leung
Jeffrey S Fleitman
Michele C Rizzolio
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of LT96028A publication Critical patent/LT96028A/xx
Publication of LT4052B publication Critical patent/LT4052B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
LT96-028A 1993-09-15 1996-03-15 Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof LT4052B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12184193A 1993-09-15 1993-09-15

Publications (2)

Publication Number Publication Date
LT96028A LT96028A (en) 1996-08-26
LT4052B true LT4052B (en) 1996-10-25

Family

ID=22399119

Family Applications (1)

Application Number Title Priority Date Filing Date
LT96-028A LT4052B (en) 1993-09-15 1996-03-15 Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof

Country Status (32)

Country Link
US (2) US5543408A (no)
EP (1) EP0724581B1 (no)
JP (1) JP3411038B2 (no)
KR (1) KR100349772B1 (no)
CN (1) CN1060770C (no)
AT (1) ATE173475T1 (no)
AU (1) AU677435B2 (no)
BR (1) BR9407469A (no)
CA (1) CA2171836C (no)
CZ (1) CZ292423B6 (no)
DE (1) DE69414720T2 (no)
DK (1) DK0724581T3 (no)
ES (1) ES2123831T3 (no)
FI (1) FI119639B (no)
HK (1) HK1012624A1 (no)
HU (1) HU217300B (no)
IL (1) IL110970A (no)
LT (1) LT4052B (no)
LV (1) LV11326B (no)
MX (1) MXPA94007099A (no)
NO (1) NO314727B1 (no)
NZ (1) NZ273801A (no)
PH (1) PH30685A (no)
PL (1) PL178522B1 (no)
RO (2) RO118075B1 (no)
RU (1) RU2132849C1 (no)
SG (1) SG55006A1 (no)
SI (1) SI9420052B (no)
TW (1) TW370527B (no)
UA (1) UA49797C2 (no)
WO (1) WO1995007902A1 (no)
ZA (1) ZA947088B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
IN188985B (no) 1998-12-09 2002-11-30 Biocon Ltd
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20050187170A1 (en) * 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
EP1667987B1 (en) * 2003-09-11 2008-07-23 Sandoz AG Process for the production of mycophenolate mofetil
US7683188B2 (en) * 2004-04-26 2010-03-23 TEVA Gyógyszergyár Zártkōrūen Mūkōdō Részvénytársaság Process for preparation of mycophenolic acid and ester derivatives thereof
CA2555454C (en) * 2004-04-27 2009-12-15 Sandor Molnar Mycophenolate mofetil impurity
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
CN101014584A (zh) * 2004-07-20 2007-08-08 特瓦药厂私人有限公司 结晶霉酚酸钠的制备方法
CN100383520C (zh) * 2004-09-20 2008-04-23 复旦大学 一种测定人血浆中霉酚酸及其代谢物的方法
EP1917010A2 (en) * 2005-02-08 2008-05-07 Aspreva Pharmaceuticals SA Compositions and methods for treating vascular, autoimmune and inflammatory diseases
US20060235009A1 (en) * 2005-02-08 2006-10-19 Richard Glickman Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
US20080280977A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
CA2655061A1 (en) 2006-06-27 2008-01-03 Sandoz Ag New method for salt preparation
CN101953807A (zh) * 2010-10-09 2011-01-26 山西普德药业有限公司 一种注射用吗替麦考酚酯冻干粉针剂及其制备方法
KR101814474B1 (ko) 2013-03-14 2018-01-12 엘커메스 파마 아일랜드 리미티드 푸마레이트의 프로드럭 및 다양한 질환을 치료하는데 있어서의 이들의 용도
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US9168246B2 (en) * 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
CA2940845C (en) 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US11918684B2 (en) 2017-03-13 2024-03-05 Liqmeds Worldwide Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
AU2022230995A1 (en) 2021-03-03 2023-09-14 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753935A (en) 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328213A (en) * 1979-11-28 1982-05-04 Schering Corporation Stable injectable labetalol formulation
US4478829A (en) * 1983-04-28 1984-10-23 Armour Pharmaceutical Company Pharmaceutical preparation containing purified fibronectin

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753935A (en) 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US4786637A (en) 1987-01-30 1988-11-22 Syntex (U.S.A.) Inc. Treatment of allograft rejection with mycophenolic acid morpholinoethylester and derivatives thereof
US4808592A (en) 1987-01-30 1989-02-28 Syntex (U.S.A.) Inc. Method of treating diseases by administering morpholinoethylester of mycophenolic acid and derivatives thereof
US4948793A (en) 1987-01-30 1990-08-14 Syntex (U.S.A.) Inc. Treatment of autoimmune diseases with the morpholinoethyl ester of mycophenolic acid, and derivatives thereof
US4952579A (en) 1987-01-30 1990-08-28 Syntex (U.S.A.) Inc. Method of treating diseases by administering morpholino-ethylester of mycophenolic acid or derivatives thereof
US4992467A (en) 1987-01-30 1991-02-12 Syntex (U.S.A.) Inc. Treatment of autoimmune diseases with mycophenolic acid, and derivatives and formulations thereof

Also Published As

Publication number Publication date
NO961075D0 (no) 1996-03-15
CZ292423B6 (cs) 2003-09-17
IL110970A (en) 1999-01-26
HU9600652D0 (en) 1996-05-28
SI9420052B (sl) 2004-02-29
PH30685A (en) 1997-09-16
DK0724581T3 (da) 1999-08-02
SI9420052A (en) 1996-12-31
TW370527B (en) 1999-09-21
CZ78896A3 (en) 1996-10-16
SG55006A1 (en) 1998-12-21
CA2171836A1 (en) 1995-03-23
NO314727B1 (no) 2003-05-12
FI961169A (fi) 1996-03-13
EP0724581B1 (en) 1998-11-18
AU677435B2 (en) 1997-04-24
RU2132849C1 (ru) 1999-07-10
PL313480A1 (en) 1996-07-08
JPH09502721A (ja) 1997-03-18
IL110970A0 (en) 1994-11-28
RO118427B1 (ro) 2003-05-30
MXPA94007099A (es) 2004-01-23
CN1131420A (zh) 1996-09-18
ZA947088B (en) 1996-03-14
NZ273801A (en) 1997-10-24
DE69414720D1 (de) 1998-12-24
HK1012624A1 (en) 1999-08-06
KR100349772B1 (ko) 2002-12-28
ATE173475T1 (de) 1998-12-15
RO118075B1 (ro) 2003-01-30
DE69414720T2 (de) 1999-04-08
LT96028A (en) 1996-08-26
BR9407469A (pt) 1996-11-12
FI961169A0 (fi) 1996-03-13
CA2171836C (en) 2006-11-14
CN1060770C (zh) 2001-01-17
FI119639B (fi) 2009-01-30
HU217300B (hu) 1999-12-28
WO1995007902A1 (en) 1995-03-23
US5545637A (en) 1996-08-13
NO961075L (no) 1996-03-15
JP3411038B2 (ja) 2003-05-26
PL178522B1 (pl) 2000-05-31
UA49797C2 (uk) 2002-10-15
HUT75119A (en) 1997-04-28
LV11326A (lv) 1996-06-20
US5543408A (en) 1996-08-06
AU7723894A (en) 1995-04-03
LV11326B (en) 1996-10-20
EP0724581A1 (en) 1996-08-07
ES2123831T3 (es) 1999-01-16

Similar Documents

Publication Publication Date Title
LT4052B (en) Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof
JP6182262B2 (ja) 抗がん剤を含む安定な水溶性医薬組成物
US6342530B1 (en) Composition and method for parenteral administration of ibuprofen d,l- or l-lysine salt
PL199846B1 (pl) Kompozycja farmaceutyczna dronedaronu do podawania pozajelitowego
AU2021269450A1 (en) Parenteral Formulation comprising Siponimod
WO2018177232A1 (zh) 难溶性复合物或其溶剂合物、药物组合物及其应用
KR102099711B1 (ko) TGF-β1 유전자의 발현을 억제하는 단일-가닥 핵산 분자를 안정적으로 함유하는 조성물
US5972912A (en) Method for lyophilizing ifosfamide
EP2440180B1 (en) Ipamorelin diacetate injection and infusion solutions
WO2021001805A1 (en) Stable dipyridamole formulations and their methods of preparation
CA2503087A1 (en) Intravenous formulations of pyridoxal 5'-phosphate and method of preparation
JPH0158161B2 (no)
WO2011061761A2 (en) Pharmaceutical composition for parenteral use
JPS639490B2 (no)
JPS6352608B2 (no)

Legal Events

Date Code Title Description
MK9A Expiry of a patent

Effective date: 20140912